Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-10-07

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)

CEO James Foster was paid $15,435,220 in fiscal year 2025, ↑ up 14.6% from fiscal year 2024, the 49th percentile of its disclosed peer group (SEC filing 0001104659-26-037367 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$15,435,220 ↑
James Foster total, FY2025
49th
CEO pay percentile vs peers
251:1
CEO-to-median pay ratio
93.84%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- James Foster (Chair, President and Chief Executive Officer), FY2025 total compensation $15,435,220 (base salary $1,545,636) [exec_comp, SEC accession 0001104659-26-037367, filed 2026-03-31]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

CRL's next annual pay disclosure, estimated March 29, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
James Foster$1,545,636—$11,601,089$0$2,182,666$0$105,829$15,435,220
Chair, President and Chief Executive Officer
Birgit Girshick760,960—4,123,6240861,8000152,0085,898,392
Corporate Executive Vice President, Chief Operating Officer
Joseph LaPlume570,167—2,260,4590563,6120119,1073,513,345
Corporate Executive Vice President, Corporate Development & Strategy
Victoria Creamer553,753—2,106,4580547,3860124,7903,332,387
Corporate Executive Vice President and Chief People Officer
Michael Knell448,11830,0001,195,4590347,500086,6072,107,684
Interim Chief Financial Officer, Corporate Senior Vice President, and Chief Accounting Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
James Foster$15,435,220$13,473,609$14,096,924↑ +1,961,611
Birgit Girshick5,898,3925,056,4754,989,672↑ +841,917
Joseph LaPlume3,513,3452,980,9593,058,456↑ +532,386
Victoria Creamer3,332,3872,806,632—↑ +525,755
Michael Knell2,107,684———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CRL reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Peer Teardown Report

$15,435,220 James Foster total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of October 7, 2026 · Source: 0001104659-26-037367 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for CRL

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
CRLon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order CRL

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against CRL
17 companies name CRL as a compensation peer

Each company listed discloses CRL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CRL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Abraham CeesayDirector$320,708
Craig B. ThompsonIndependent Director$340,859
Deborah T. KochevarFormer director (through FY2025)$21,250
George E. MassaroFormer director (through FY2025)$28,750
George Llado, SrIndependent Director$325,859
Mark EnyedyIndependent Director$320,708
Martin MackayChair of the Board$365,859
Nancy C. AndrewsIndependent Director$340,859
Paul GravesIndependent Director$345,708
Reshema Kemps-PolancoIndependent Director$340,859
Richard F. WallmanFormer director (through FY2025)$26,250
Robert BertoliniFormer director (through FY2025)$22,500
Steven BargIndependent Director$320,708
Virginia M. WilsonIndependent Director$345,859
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Glenn ColemanEVP & Chief Financial Officer2026-05-01A21,112$166$3,499,947CommonForm 4 ↗
James C. FosterDirector2026-05-08A42217874,956CommonForm 4 ↗
James C. FosterDirector2026-05-08A1,438178255,418CommonForm 4 ↗
George Llado, SrDirector2026-05-08A45017879,929CommonForm 4 ↗
Nancy C. AndrewsDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Martin MackayDirector2026-05-08A1,407178249,911CommonForm 4 ↗
Craig B. ThompsonDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Virginia M. WilsonDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Reshema Kemps-PolancoDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Martin MackayDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Paul GravesDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Steven BargDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Reshema Kemps-PolancoDirector2026-05-08A53517895,027CommonForm 4 ↗
Mark EnyedyDirector2026-05-08A1,438178255,418CommonForm 4 ↗
George Llado, SrDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Abraham CeesayDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Nancy C. AndrewsDirector2026-05-12A3,96400CommonForm 4 ↗
Nancy C. AndrewsDirector2026-05-12D3,96400CommonForm 4 ↗
Joseph LaPlumeEVP, Corp Strategy & Develop2026-05-26D24316038,953CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-05-26D501608,015CommonForm 4 ↗
Mark MintzEVP, Chief Information Officer2026-05-26D6416010,259CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-05-26D16816026,930CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-05-26D37616060,273CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-05-26D19816031,739CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-05-27D10515716,457CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-05-27D14815723,196CommonForm 4 ↗
Joseph LaPlumeEVP, Corp Strategy & Develop2026-05-27D18515728,995CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-05-27D24215737,929CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-05-27D371575,799CommonForm 4 ↗
Mark MintzEVP, Chief Information Officer2026-05-27D471577,366CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-05-29A9,9611811,800,052CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-05-29A1,837181331,964CommonForm 4 ↗
Joseph LaPlumeEVP, Corp Strategy & Develop2026-05-29A5,257181949,992CommonForm 4 ↗
Glenn ColemanEVP & Chief Financial Officer2026-05-29A6,6401811,199,914CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-05-29A4,361181788,076CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-05-29A5,135181927,946CommonForm 4 ↗
Mark MintzEVP, Chief Information Officer2026-05-29A2,534181457,919CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-05-30D1,204181217,575CommonForm 4 ↗
Joseph LaPlumeEVP, Corp Strategy & Develop2026-05-30D744181134,448CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-05-30D616181111,317CommonForm 4 ↗
James C. FosterDirector2026-05-30D1,596181288,413CommonForm 4 ↗
Mark MintzEVP, Chief Information Officer2026-05-30D30518155,117CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-05-30D55118199,571CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-05-30D15218127,468CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-05-31D19418135,058CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-05-31D37818168,308CommonForm 4 ↗
Mark MintzEVP, Chief Information Officer2026-05-31D6418111,565CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-05-31D481818,674CommonForm 4 ↗
Joseph LaPlumeEVP, Corp Strategy & Develop2026-05-31D23518142,467CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-05-31D17018130,721CommonForm 4 ↗
Steven BargDirector2026-06-02A42217573,761CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-06-05A1,52900CommonForm 4 ↗
James C. FosterDirector2026-06-05A20,00000CommonForm 4 ↗
James C. FosterDirector2026-06-05D20,00000CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-06-05D1,52900CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-06-05A3,38600CommonForm 4 ↗
James C. FosterDirector2026-06-05A10,00000CommonForm 4 ↗
James C. FosterDirector2026-06-05A153,36100CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-06-05D3,38600CommonForm 4 ↗
James C. FosterDirector2026-06-05D10,00000CommonForm 4 ↗
James C. FosterDirector2026-06-05D153,36100CommonForm 4 ↗
James C. FosterDirector2026-06-29D75,00022516,875,000CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-05D5,0462631,327,098CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-08-06D4,17900Derivative, Class A CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-08-06A4,179180750,799CommonForm 4 ↗
Dividend-equivalent accruals2026-08-06—2,345——1 insider, 3 accrual rows
Michael KnellSVP, Finance and CAO2026-08-06D404259104,446CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06A40418072,583CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D482265127,812Common, open-market saleForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D810261211,775Common, open-market saleForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D901261234,828Common, open-market saleForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D1,274259330,055Common, open-market saleForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D620264163,643Common, open-market saleForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D1,205259311,529CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-08-06D4,1792591,083,030CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D736259190,278CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06A736208153,412CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06A1,205194233,915CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D21326255,885Common, open-market saleForm 4 ↗
James C. FosterDirector2026-08-10D28,73300Derivative, Class A CommonForm 4 ↗
James C. FosterDirector2026-08-10D28,7332757,901,575CommonForm 4 ↗
James C. FosterDirector2026-08-10A28,7331805,162,171CommonForm 4 ↗
Joseph LaPlumeEVP, Corp Strategy & Develop2026-08-10D25700CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-11D3,71400Derivative, Class A CommonForm 4 ↗
Birgit GirshickDirector2026-08-11D6,50000Derivative, Class A CommonForm 4 ↗
Birgit GirshickDirector2026-08-11A6,5001801,167,790CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-11D3,7142801,038,657CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-11A3,714180667,257CommonForm 4 ↗
Birgit GirshickDirector2026-08-11D6,5002801,819,350CommonForm 4 ↗
Nancy C. AndrewsDirector2026-08-18D573285163,443CommonForm 4 ↗
Nancy C. AndrewsDirector2026-08-18A57316494,144CommonForm 4 ↗
Dividend-equivalent accruals2026-08-18—573——1 insider, 1 accrual row
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-19A2,039194395,811CommonForm 4 ↗
Birgit GirshickDirector2026-08-19D52800CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-19D2,03900Derivative, Class A CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-19D2,039294599,711CommonForm 4 ↗
James C. FosterDirector2026-08-25D33,56130010,068,300CommonForm 4 ↗
James C. FosterDirector2026-08-25A12,4292082,590,701CommonForm 4 ↗
James C. FosterDirector2026-08-25D12,42900Derivative, Class A CommonForm 4 ↗
James C. FosterDirector2026-08-25D21,13200Derivative, Class A CommonForm 4 ↗
James C. FosterDirector2026-08-25A21,1321944,102,144CommonForm 4 ↗
Glenn ColemanEVP & Chief Financial Officer2026-09-30A102972,974CommonForm 4 ↗
Dividend-equivalent accruals2026-10-05—981——1 insider, 1 accrual row
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-10-05D981308302,580CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-10-05A981208204,480CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 107 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Glenn ColemanEVP & Chief Financial Officer2026-05-01A21,112$166$3,499,947CommonForm 4 ↗
James C. FosterDirector2026-05-08A42217874,956CommonForm 4 ↗
James C. FosterDirector2026-05-08A1,438178255,418CommonForm 4 ↗
George Llado, SrDirector2026-05-08A45017879,929CommonForm 4 ↗
Nancy C. AndrewsDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Martin MackayDirector2026-05-08A1,407178249,911CommonForm 4 ↗
Craig B. ThompsonDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Virginia M. WilsonDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Reshema Kemps-PolancoDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Martin MackayDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Paul GravesDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Steven BargDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Reshema Kemps-PolancoDirector2026-05-08A53517895,027CommonForm 4 ↗
Mark EnyedyDirector2026-05-08A1,438178255,418CommonForm 4 ↗
George Llado, SrDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Abraham CeesayDirector2026-05-08A1,438178255,418CommonForm 4 ↗
Nancy C. AndrewsDirector2026-05-12A3,96400CommonForm 4 ↗
Nancy C. AndrewsDirector2026-05-12D3,96400CommonForm 4 ↗
Joseph LaPlumeEVP, Corp Strategy & Develop2026-05-26D24316038,953CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-05-26D501608,015CommonForm 4 ↗
Mark MintzEVP, Chief Information Officer2026-05-26D6416010,259CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-05-26D16816026,930CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-05-26D37616060,273CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-05-26D19816031,739CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-05-27D10515716,457CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-05-27D14815723,196CommonForm 4 ↗
Joseph LaPlumeEVP, Corp Strategy & Develop2026-05-27D18515728,995CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-05-27D24215737,929CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-05-27D371575,799CommonForm 4 ↗
Mark MintzEVP, Chief Information Officer2026-05-27D471577,366CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-05-29A9,9611811,800,052CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-05-29A1,837181331,964CommonForm 4 ↗
Joseph LaPlumeEVP, Corp Strategy & Develop2026-05-29A5,257181949,992CommonForm 4 ↗
Glenn ColemanEVP & Chief Financial Officer2026-05-29A6,6401811,199,914CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-05-29A4,361181788,076CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-05-29A5,135181927,946CommonForm 4 ↗
Mark MintzEVP, Chief Information Officer2026-05-29A2,534181457,919CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-05-30D1,204181217,575CommonForm 4 ↗
Joseph LaPlumeEVP, Corp Strategy & Develop2026-05-30D744181134,448CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-05-30D616181111,317CommonForm 4 ↗
James C. FosterDirector2026-05-30D1,596181288,413CommonForm 4 ↗
Mark MintzEVP, Chief Information Officer2026-05-30D30518155,117CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-05-30D55118199,571CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-05-30D15218127,468CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-05-31D19418135,058CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-05-31D37818168,308CommonForm 4 ↗
Mark MintzEVP, Chief Information Officer2026-05-31D6418111,565CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-05-31D481818,674CommonForm 4 ↗
Joseph LaPlumeEVP, Corp Strategy & Develop2026-05-31D23518142,467CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-05-31D17018130,721CommonForm 4 ↗
Steven BargDirector2026-06-02A42217573,761CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-06-05A1,52900CommonForm 4 ↗
James C. FosterDirector2026-06-05A20,00000CommonForm 4 ↗
James C. FosterDirector2026-06-05D20,00000CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-06-05D1,52900CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-06-05A3,38600CommonForm 4 ↗
James C. FosterDirector2026-06-05A10,00000CommonForm 4 ↗
James C. FosterDirector2026-06-05A153,36100CommonForm 4 ↗
Birgit GirshickChief Executive Officer2026-06-05D3,38600CommonForm 4 ↗
James C. FosterDirector2026-06-05D10,00000CommonForm 4 ↗
James C. FosterDirector2026-06-05D153,36100CommonForm 4 ↗
James C. FosterDirector2026-06-29D75,00022516,875,000CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-05D5,0462631,327,098CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-08-06D4,17900Derivative, Class A CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-08-06A4,179180750,799CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D40400Derivative, Class A CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D404259104,446CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06A40418072,583CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D482265127,812Common, open-market saleForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D810261211,775Common, open-market saleForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D901261234,828Common, open-market saleForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D1,274259330,055Common, open-market saleForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D620264163,643Common, open-market saleForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D1,205259311,529CommonForm 4 ↗
Victoria CreamerEVP & Chief People Officer2026-08-06D4,1792591,083,030CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D736259190,278CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06A736208153,412CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06A1,205194233,915CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D21326255,885Common, open-market saleForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D73600Derivative, Class A CommonForm 4 ↗
Michael KnellSVP, Finance and CAO2026-08-06D1,20500Derivative, Class A CommonForm 4 ↗
James C. FosterDirector2026-08-10D28,73300Derivative, Class A CommonForm 4 ↗
James C. FosterDirector2026-08-10D28,7332757,901,575CommonForm 4 ↗
James C. FosterDirector2026-08-10A28,7331805,162,171CommonForm 4 ↗
Joseph LaPlumeEVP, Corp Strategy & Develop2026-08-10D25700CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-11D3,71400Derivative, Class A CommonForm 4 ↗
Birgit GirshickDirector2026-08-11D6,50000Derivative, Class A CommonForm 4 ↗
Birgit GirshickDirector2026-08-11A6,5001801,167,790CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-11D3,7142801,038,657CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-11A3,714180667,257CommonForm 4 ↗
Birgit GirshickDirector2026-08-11D6,5002801,819,350CommonForm 4 ↗
Nancy C. AndrewsDirector2026-08-18D573285163,443CommonForm 4 ↗
Nancy C. AndrewsDirector2026-08-18A57316494,144CommonForm 4 ↗
Nancy C. AndrewsDirector2026-08-18D57300Derivative, Class A CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-19A2,039194395,811CommonForm 4 ↗
Birgit GirshickDirector2026-08-19D52800CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-19D2,03900Derivative, Class A CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-08-19D2,039294599,711CommonForm 4 ↗
James C. FosterDirector2026-08-25D33,56130010,068,300CommonForm 4 ↗
James C. FosterDirector2026-08-25A12,4292082,590,701CommonForm 4 ↗
James C. FosterDirector2026-08-25D12,42900Derivative, Class A CommonForm 4 ↗
James C. FosterDirector2026-08-25D21,13200Derivative, Class A CommonForm 4 ↗
James C. FosterDirector2026-08-25A21,1321944,102,144CommonForm 4 ↗
Glenn ColemanEVP & Chief Financial Officer2026-09-30A102972,974CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-10-05D98100Derivative, Class A CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-10-05D981308302,580CommonForm 4 ↗
Shannon M. ParisottoCEVP, Disc & Safety Assessment2026-10-05A981208204,480CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Victoria CreamerRSU2025-05-30——6,252—$847,959
Birgit GirshickRSU2025-05-30——12,239—1,659,976
Birgit GirshickPSU2025-05-306,10818,795—37,5902,463,649
Joseph LaPlumeRSU2025-05-30——6,709—909,942
Victoria CreamerPSU2025-05-303,1209,601—19,2021,258,499
Joseph LaPlumePSU2025-05-303,34810,303—20,6061,350,517
Flavia H. PeaseRSU2025-05-30——7,152—970,026
Flavia H. PeasePSU2025-05-303,56910,982—21,9641,439,521
James FosterPSU2025-05-3022,96270,652—141,3049,261,064
Michael KnellRSU2025-11-06——2,926—499,995
James FosterRSU2025-05-30——17,253—2,340,024
Michael KnellPSU2025-05-301,0303,170—6,340415,524
Michael KnellRSU2025-05-30——2,064—279,940
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Victoria Creamer$847,959$1,258,499$059.7%
Birgit Girshick1,659,9762,463,649059.7%
Joseph LaPlume909,9421,350,517059.7%
Flavia H. Pease970,0261,439,521059.7%
James Foster2,340,0249,261,064079.8%
Michael Knell779,935415,524034.8%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Victoria CreamerOption3,110337.99—
Joseph LaPlumeOption3,476337.99—
Birgit GirshickOption3,659337.99—
James FosterOption6,011244.41—
Joseph LaPlumePSU26,660—5,429,576
Victoria CreamerRSU9,107—1,854,732
Michael KnellOption1,006337.99—
Birgit GirshickOption6,500179.66—
Birgit GirshickOption4,573194.12—
Birgit GirshickOption6,542208.44—
Joseph LaPlumeOption6,685179.66—
Joseph LaPlumeOption1,120244.41—
Victoria CreamerOption4,179179.66—
Victoria CreamerOption2,410194.12—
PeaseOption4,649245.88—
PeaseOption3,317244.41—
Victoria CreamerOption1,009244.41—
Birgit GirshickPSU48,598—9,897,469
Birgit GirshickRSU17,638—3,592,155
James FosterRSU17,253—3,513,746
Joseph LaPlumeRSU16,574—3,375,461
Michael KnellRSU6,698—1,364,115
James FosterPSU183,136—37,297,478
Victoria CreamerPSU24,843—5,059,525
Michael KnellPSU8,197—1,669,401
James FosterOption28,733179.66—
James FosterOption18,869337.99—
James FosterOption14,088194.12—
James FosterOption18,644208.44—
Birgit GirshickOption1,659244.41—
Joseph LaPlumeOption2,626194.12—
Joseph LaPlumeOption3,598208.44—
Victoria CreamerOption3,353208.44—
PeaseOption1,226208.44—
05

Incentive-plan design — the Compensation Discussion & Analysis

The purpose of our compensation program is to motivate, recruit and retain the strongest possible management team, and simultaneously align management s interest with those of our shareholders. Our philosophy behind the Compensation Program is that it should appropriately align executive compensation with both the short- and long-term performance of the Company and our commitment to our shareholders.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantPay Governance
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-0541,356,1392,716,25130,30593.84%Passed
20252025-05-2040,218,8701,432,240102,25296.56%Passed
20242024-05-0843,833,5032,299,36255,33595.02%Passed
20232023-05-0940,252,1615,727,67831,33887.54%Passed
20222022-05-1039,792,7205,179,35224,44688.48%Passed
20212021-05-0638,268,8496,446,97627,51885.58%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-0593.84%a
20252025-05-2096.56%b
20242024-05-0895.02%c

a. Voting standard not stated in the filing.

b. Approved under the standard stated in the filing — “Broker non-votes (if applicable) and abstentions will have no effect on the voting on any matter that requires the affirmative vote of a majority of the votes cast on the matter.”.

c. Approved under the standard stated in the filing — “Broker non-votes (if applicable) and abstentions will have no effect on the voting on any matter that requires the affirmative vote of a majority of the votes cast on the matter.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)251 : 1
CEO total compensation$15,435,220
Median employee compensation$61,430
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Martin MackayIndependent · Board Chair · Lead Independent Director$110,000$127,691$128,168$0$0$365,859
Virginia M. WilsonIndependent90,000127,691128,16800345,859
Paul GravesIndependent · Newly elected90,000127,748127,96000345,708
Craig B. ThompsonIndependent · Compensation85,000127,691128,16800340,859
Reshema Kemps-PolancoIndependent · Compensation (Chair)85,000127,691128,16800340,859
Nancy C. AndrewsIndependent85,000127,691128,16800340,859
George Llado, SrIndependent70,000127,691128,16800325,859
Steven BargIndependent · Compensation · Newly elected65,000127,748127,96000320,708
Mark EnyedyIndependent · Newly elected65,000127,748127,96000320,708
Abraham CeesayNot independent · Newly elected65,000127,748127,96000320,708
George E. MassaroIndependent · Not standing for re-election · Departed during FY28,750000028,750
Richard F. WallmanIndependent · Not standing for re-election · Departed during FY26,250000026,250
Robert BertoliniIndependent · Not standing for re-election · Departed during FY22,500000022,500
Deborah T. KochevarIndependent · Not standing for re-election · Departed during FY21,250000021,250
James C. FosterEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$65,000
Annual equity retainer$255,500
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)25,000 / 20,000 / 20,000
Stock ownership guideline$325,000
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$908,750
Equity awards (grant-date value)$1,277,138
All other compensation$0
Total cost of the board$2,185,888

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies CHARLES RIVER LABORATORIES INTERNATIONAL, INC. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including CHARLES RIVER LABORATORIES INTERNATIONAL, INC..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Thermo Fisher Scientific Inc.2025Marc Casper$1,785,534$65,730,211$7,951,377$3,742,123$79,923,350
2Baxter International Inc.2025Andrew Hider499,31523,133,5183,185,053820,12529,805,182
3Gilead Sciences, Inc.2025Daniel O'Day1,795,19215,238,4024,500,0604,848,12028,437,198
4IQVIA Holdings Inc.2025Ari Bousbib1,800,00015,749,9574,528,3174,966,12728,128,245
5Pfizer Inc.2025Albert Bourla1,800,0009,442,7058,998,1415,400,00027,585,301
6Amgen Inc.2025Robert Bradway1,925,40912,599,5895,399,9963,907,00024,693,120
7Abbott Laboratories2025Robert Ford1,500,0008,787,3788,788,4301,968,75024,198,660
8Biogen Inc.2025Christopher Viehbacher1,727,88518,368,87503,190,87523,646,004
9Boston Scientific Corporation2025Michael Mahoney1,442,60313,608,0563,749,9804,002,00123,532,050
10Bristol-Myers Squibb Company2025Christopher Boerner1,586,34616,061,39903,754,68421,879,919
11Vertex Pharmaceuticals Incorporated2025Reshma Kewalramani1,600,00015,002,27004,118,64021,144,261
12Jazz Pharmaceuticals Public Company Limited2025Renee Gala1,003,26916,138,43301,980,00019,151,558
13Becton, Dickinson and Company2025Thomas Polen1,395,4639,991,8543,311,8611,852,01017,129,140
14Hologic Inc.2024Stephen MacMillan1,212,6289,141,4682,937,4771,990,41315,819,261
15Quest Diagnostics Incorporated2025James Davis1,250,0008,762,8612,999,8732,205,84415,498,479
16CHARLES RIVER LABORATORIES INTERNATIONAL, INC.2025James Foster1,545,63611,601,08902,182,66615,435,220
17IDEXX Laboratories Inc.2025Jonathan Mazelsky1,150,0005,399,8815,400,0012,593,00014,580,122
18Waters Corporation2025Udit Batra1,150,0007,430,2472,999,9222,371,87513,973,044
19Revvity2025Prahlad R. Singh1,129,2317,694,9852,559,1522,385,45013,809,549
20Agilent Technologies, Inc.2025Padraig McDonnell1,141,3458,169,8502,017,7591,436,80912,827,236
21Fortrea Holdings, Inc.2025Anshul Thakral401,92310,479,1690687,50011,584,483
22STERIS plc2026Daniel Carestio1,095,7074,333,9514,334,2511,725,00711,508,522
23Medpace Holdings, Inc.2025August Troendle937,41709,999,999011,443,766
24Illumina, Inc.2025Jacob Thaysen1,000,0008,763,12201,155,00011,018,895
25Bio-Rad Laboratories, Inc.2025Norman Schwartz1,089,8774,856,5741,458,975562,0887,995,841
26Regeneron Pharmaceuticals, Inc.2025Leonard Schleifer1,979,922——3,682,6557,280,549
27Teleflex Incorporated2025Liam Kelly1,144,4002,005,6042,886,518227,2806,732,419
28Catalent, Inc.2023Alessandro Maselli925,0003,850,2161,650,01906,583,672
29Avantor, Inc.2025Emmanuel Ligner379,2972,499,9902,499,998330,0385,895,624
30Myriad Genetics, Inc.2025Samraat Raha856,9013,989,7290814,6605,686,740
—Icon plc——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.139%PSU 60 · RSU 40Yes — Three-year rTSRPay Governance
Abbott Laboratories75.0%Options 50 · PSU 50NoMeridian Compensation Partners, LLC
Agilent Technologies, Inc.not disclosedPSU 60 · Options 20 · RSU 20NoSemler Brossy
Amgen Inc.136.0%PSU 50 · Options 30 · RSU 20Yes — relative TSRFrederic W. Cook & Co., Inc. (FW Cook)
Avantor, Inc.56.9%PSU 50 · Options 25 · RSU 25Yes — TSR Relative to Comparator GroupFW Cook
Baxter International Inc.not disclosednot disclosedNoAon Consulting, Inc. (Aon)
Becton, Dickinson and Company85%PSU 50 · Options 25 · RSU 25NoSemler Brossy
Bio-Rad Laboratories, Inc.not disclosednot disclosednot disclosedCompensia, Inc.
Biogen Inc.127%PSU 60 · RSU 40YesPay Governance
Boston Scientific Corporation173%PSU 50 · RSU 25 · Options 25NoSemler Brossy Consulting Group, LLC
Bristol-Myers Squibb Company157.66%PSU 60 · MSU 40Yes — 3-Year Relative TSR CAGRFarient Advisors LLC
Catalent, Inc.0%PSU 50 · Option 30 · RSU 20NoFrederic W. Cook & Co., Inc.
Fortrea Holdings, Inc.68.5%PSU 50 · RSU 50NoPay Governance LLC
Gilead Sciences, Inc.180%PSU 50 · Options 25 · RSU 25Yes — Relative TSRFW Cook
Hologic Inc.109%PSU 50 · RSU 25 · Option 25NoPearl Meyer & Partners, LLC
Icon plcnot disclosednot disclosednot disclosednot disclosed
IDEXX Laboratories Inc.140%Options 50 · PSU 50NoFarient
Illumina, Inc.1155%not disclosedYes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology IndexAon (Aon's Human Capital Practice, a division of Aon, plc)
IQVIA Holdings Inc.not disclosedPSU 75 · Options 25YesMeridian Compensation Partners, LLC
Jazz Pharmaceuticals Public Company Limited150%PSU 50 · RSU 50Yes — Relative TSRAon
Medpace Holdings, Inc.52.5%Options 100not disclosedTotal Compensation Solutions (TCS)
Myriad Genetics, Inc.89%RSU 50 · PSU 50YesMercer, LLC
Pfizer Inc.150%PSU 50 · MSU 50Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG)Meridian Compensation Partners, LLC
Quest Diagnostics Incorporated113.9%PSU 50 · RSU 25 · Options 25Yes — Relative TSRSemler Brossy
Regeneron Pharmaceuticals, Inc.155%Options 60 · RSU 40not disclosedPay Governance LLC
Revvity124%PSU 50 · RSU 25 · Options 25NoPearl Meyer
STERIS plc125.1%RSU 50 · Options 50not disclosedFrederic W. Cook & Co., Inc.
Teleflex Incorporated25.9%Options 55 · RSU 25 · PSU 20Yes — Absolute TSRFW Cook
Thermo Fisher Scientific Inc.99.8%PSU 50 · Options 50Yes — Relative TSRPearl Meyer
Vertex Pharmaceuticals Incorporatednot disclosedPSU 55 · RSU 45Nonot disclosed
Waters Corporation110%PSU 50 · Options 35 · RSU 15Yes — Relative Total Shareholder Return (rTSR)Pearl Meyer

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at CHARLES RIVER LABORATORIES INTERNATIONAL, INC. in fiscal 2025?
As disclosed, James Foster (Chair, President and Chief Executive Officer) was the highest-paid executive at CHARLES RIVER LABORATORIES INTERNATIONAL, INC. in fiscal 2025, with total compensation of $15,435,220.
How does CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s chief executive pay compare to its disclosed peer group?
As disclosed, James Foster's total compensation ranked at the 49th percentile of CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s disclosed peer group.
What is CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s CEO-to-median employee pay ratio?
As disclosed, CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s CEO-to-median employee pay ratio was 251:1.
How did shareholders vote on CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s executive compensation?
As disclosed, 93.84% of shareholders supported CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s executive compensation in the latest say-on-pay vote.
How much does CHARLES RIVER LABORATORIES INTERNATIONAL, INC. spend in total on board compensation for fiscal 2025?
As disclosed, CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported total board compensation of $2,185,888 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, James FosterDEF 14A2026-03-310001104659-26-037367Section “2025 Summary Compensation Table”. As printed: 15,435,220. Filing ↗machine: r1 · c53 · span 1119658–1119668
2Section 01, Birgit GirshickDEF 14A2026-03-310001104659-26-037367Section “2025 Summary Compensation Table”. As printed: 5,898,392. Filing ↗machine: r6 · c53 · span 1145570–1145579
3Section 01, Joseph LaPlumeDEF 14A2026-03-310001104659-26-037367Section “2025 Summary Compensation Table”. As printed: 3,513,345. Filing ↗machine: r9 · c53 · span 1161004–1161013
4Section 01, Victoria CreamerDEF 14A2026-03-310001104659-26-037367Section “2025 Summary Compensation Table”. As printed: 3,332,387. Filing ↗machine: r12 · c53 · span 1176439–1176448
5Section 01, Michael KnellDEF 14A2026-03-310001104659-26-037367Section “2025 Summary Compensation Table”. As printed: 2,107,684. Filing ↗machine: r4 · c53 · span 1135139–1135148
6Section 03, Victoria Creamer RSUDEF 14A1900-01-010001104659-26-037367Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1363642–1363649
7Section 03, Birgit Girshick RSUDEF 14A1900-01-010001104659-26-037367Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1305811–1305820
8Section 03, Birgit Girshick PSUDEF 14A1900-01-010001104659-26-037367Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1316537–1316546
9Section 03, Joseph LaPlume RSUDEF 14A1900-01-010001104659-26-037367Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1334714–1334721
10Section 03, Victoria Creamer PSUDEF 14A1900-01-010001104659-26-037367Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1374365–1374374
11Section 03, Joseph LaPlume PSUDEF 14A1900-01-010001104659-26-037367Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1345413–1345422
12Section 03, Flavia H. Pease RSUDEF 14A1900-01-010001104659-26-037367Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1392546–1392553
13Section 03, Flavia H. Pease PSUDEF 14A1900-01-010001104659-26-037367Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1403212–1403221
14Section 03, James Foster PSUDEF 14A1900-01-010001104659-26-037367Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1250260–1250269
15Section 03, Michael Knell RSUDEF 14A1900-01-010001104659-26-037367Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1276885–1276892
16Section 03, James Foster RSUDEF 14A1900-01-010001104659-26-037367Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1239532–1239541
17Section 03, Michael Knell PSUDEF 14A1900-01-010001104659-26-037367Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1287582–1287589
18Section 03, Michael Knell RSUDEF 14A1900-01-010001104659-26-037367Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1268439–1268446
19Section 07, pay ratioDEF 14A2026-03-310001104659-26-037367Section “CEO Pay Ratio”. As printed: 251 : 1. Filing ↗machine: span 1985635–1985638
20Section 08, Martin MackayDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 365,859. Filing ↗machine: t17 · r1 · c29 · span 480113–480120
21Section 08, Virginia M. WilsonDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 345,859. Filing ↗machine: t17 · r2 · c29 · span 483215–483222
22Section 08, Paul GravesDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 345,708. Filing ↗machine: t17 · r3 · c29 · span 486335–486342
23Section 08, Craig B. ThompsonDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 340,859. Filing ↗machine: t17 · r6 · c29 · span 495669–495676
24Section 08, Reshema Kemps-PolancoDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 340,859. Filing ↗machine: t17 · r5 · c29 · span 492568–492575
25Section 08, Nancy C. AndrewsDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 340,859. Filing ↗machine: t17 · r4 · c29 · span 489435–489442
26Section 08, George Llado, SrDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 325,859. Filing ↗machine: t17 · r7 · c29 · span 498794–498801
27Section 08, Steven BargDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 320,708. Filing ↗machine: t17 · r8 · c29 · span 501889–501896
28Section 08, Mark EnyedyDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 320,708. Filing ↗machine: t18 · r1 · c29 · span 512947–512954
29Section 08, Abraham CeesayDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 320,708. Filing ↗machine: t17 · r9 · c29 · span 505012–505019
30Section 08, George E. MassaroDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 28,750. Filing ↗
31Section 08, Richard F. WallmanDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 26,250. Filing ↗
32Section 08, Robert BertoliniDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 22,500. Filing ↗
33Section 08, Deborah T. KochevarDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 21,250. Filing ↗
34Section 08, James C. FosterDEF 14A2026-03-310001104659-26-037367Section “Director Compensation”. As printed: 0. Filing ↗
35Section 02, Glenn Coleman 2026-05-01Form 42026-05-040001100682-26-000033Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, James C. Foster 2026-05-08Form 42026-05-110001100682-26-000044Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, James C. Foster 2026-05-08Form 42026-05-110001100682-26-000044Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, George Llado, Sr 2026-05-08Form 42026-05-110001100682-26-000052Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Nancy C. Andrews 2026-05-08Form 42026-05-110001100682-26-000057Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Martin Mackay 2026-05-08Form 42026-05-110001100682-26-000059Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Craig B. Thompson 2026-05-08Form 42026-05-120001100682-26-000068Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Virginia M. Wilson 2026-05-08Form 42026-05-110001100682-26-000046Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Reshema Kemps-Polanco 2026-05-08Form 42026-05-110001100682-26-000048Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Martin Mackay 2026-05-08Form 42026-05-110001100682-26-000059Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Paul Graves 2026-05-08Form 42026-05-120001100682-26-000066Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Steven Barg 2026-05-08Form 42026-05-120001100682-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Reshema Kemps-Polanco 2026-05-08Form 42026-05-110001100682-26-000048Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Mark Enyedy 2026-05-08Form 42026-05-110001100682-26-000050Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, George Llado, Sr 2026-05-08Form 42026-05-110001100682-26-000052Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Abraham Ceesay 2026-05-08Form 42026-05-110001100682-26-000062Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Nancy C. Andrews 2026-05-12Form 42026-05-140001100682-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Nancy C. Andrews 2026-05-12Form 42026-05-140001100682-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Joseph LaPlume 2026-05-26Form 42026-05-280001100682-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Michael Knell 2026-05-26Form 42026-05-280001100682-26-000077Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Mark Mintz 2026-05-26Form 42026-05-280001100682-26-000081Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Shannon M. Parisotto 2026-05-26Form 42026-05-280001100682-26-000083Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Birgit Girshick 2026-05-26Form 42026-05-280001100682-26-000079Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Victoria Creamer 2026-05-26Form 42026-05-280001100682-26-000085Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Shannon M. Parisotto 2026-05-27Form 42026-05-280001100682-26-000083Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Victoria Creamer 2026-05-27Form 42026-05-280001100682-26-000085Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Joseph LaPlume 2026-05-27Form 42026-05-280001100682-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Birgit Girshick 2026-05-27Form 42026-05-280001100682-26-000079Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Michael Knell 2026-05-27Form 42026-05-280001100682-26-000077Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Mark Mintz 2026-05-27Form 42026-05-280001100682-26-000081Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Birgit Girshick 2026-05-29Form 42026-06-020001100682-26-000093Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Michael Knell 2026-05-29Form 42026-06-020001100682-26-000095Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Joseph LaPlume 2026-05-29Form 42026-06-020001100682-26-000097Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Glenn Coleman 2026-05-29Form 42026-06-020001100682-26-000101Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Shannon M. Parisotto 2026-05-29Form 42026-06-020001100682-26-000087Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Victoria Creamer 2026-05-29Form 42026-06-020001100682-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Mark Mintz 2026-05-29Form 42026-06-020001100682-26-000099Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Birgit Girshick 2026-05-30Form 42026-06-020001100682-26-000093Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Joseph LaPlume 2026-05-30Form 42026-06-020001100682-26-000097Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Victoria Creamer 2026-05-30Form 42026-06-020001100682-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, James C. Foster 2026-05-30Form 42026-06-020001100682-26-000091Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Mark Mintz 2026-05-30Form 42026-06-020001100682-26-000099Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Shannon M. Parisotto 2026-05-30Form 42026-06-020001100682-26-000087Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Michael Knell 2026-05-30Form 42026-06-020001100682-26-000095Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Victoria Creamer 2026-05-31Form 42026-06-020001100682-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Birgit Girshick 2026-05-31Form 42026-06-020001100682-26-000093Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Mark Mintz 2026-05-31Form 42026-06-020001100682-26-000099Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Michael Knell 2026-05-31Form 42026-06-020001100682-26-000095Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Joseph LaPlume 2026-05-31Form 42026-06-020001100682-26-000097Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Shannon M. Parisotto 2026-05-31Form 42026-06-020001100682-26-000087Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Steven Barg 2026-06-02Form 42026-06-030001100682-26-000103Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Shannon M. Parisotto 2026-06-05Form 42026-06-080001100682-26-000105Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, James C. Foster 2026-06-05Form 42026-06-080001100682-26-000109Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, James C. Foster 2026-06-05Form 42026-06-080001100682-26-000109Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Shannon M. Parisotto 2026-06-05Form 42026-06-080001100682-26-000105Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Birgit Girshick 2026-06-05Form 42026-06-080001100682-26-000107Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, James C. Foster 2026-06-05Form 42026-06-080001100682-26-000109Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, James C. Foster 2026-06-05Form 42026-06-080001100682-26-000109Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Birgit Girshick 2026-06-05Form 42026-06-080001100682-26-000107Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, James C. Foster 2026-06-05Form 42026-06-080001100682-26-000109Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, James C. Foster 2026-06-05Form 42026-06-080001100682-26-000109Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, James C. Foster 2026-06-29Form 42026-07-010001100682-26-000111Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Shannon M. Parisotto 2026-08-05Form 42026-08-060001100682-26-000120Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Victoria Creamer 2026-08-06Form 42026-08-100001100682-26-000122Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Victoria Creamer 2026-08-06Form 42026-08-100001100682-26-000122Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Victoria Creamer 2026-08-06Form 42026-08-100001100682-26-000122Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Michael Knell 2026-08-06Form 42026-08-100001100682-26-000124Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, James C. Foster 2026-08-10Form 42026-08-110001100682-26-000126Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, James C. Foster 2026-08-10Form 42026-08-110001100682-26-000126Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, James C. Foster 2026-08-10Form 42026-08-110001100682-26-000126Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Joseph LaPlume 2026-08-10Form 42026-08-110001100682-26-000128Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Shannon M. Parisotto 2026-08-11Form 42026-08-130001100682-26-000130Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Birgit Girshick 2026-08-11Form 42026-08-130001100682-26-000132Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Birgit Girshick 2026-08-11Form 42026-08-130001100682-26-000132Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Shannon M. Parisotto 2026-08-11Form 42026-08-130001100682-26-000130Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Shannon M. Parisotto 2026-08-11Form 42026-08-130001100682-26-000130Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Birgit Girshick 2026-08-11Form 42026-08-130001100682-26-000132Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Nancy C. Andrews 2026-08-18Form 42026-08-200001100682-26-000134Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Nancy C. Andrews 2026-08-18Form 42026-08-200001100682-26-000134Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Nancy C. Andrews 2026-08-18Form 42026-08-200001100682-26-000134Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Shannon M. Parisotto 2026-08-19Form 42026-08-200001100682-26-000136Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Birgit Girshick 2026-08-19Form 42026-08-200001100682-26-000138Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Shannon M. Parisotto 2026-08-19Form 42026-08-200001100682-26-000136Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Shannon M. Parisotto 2026-08-19Form 42026-08-200001100682-26-000136Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, James C. Foster 2026-08-25Form 42026-08-270001100682-26-000140Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, James C. Foster 2026-08-25Form 42026-08-270001100682-26-000140Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, James C. Foster 2026-08-25Form 42026-08-270001100682-26-000140Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, James C. Foster 2026-08-25Form 42026-08-270001100682-26-000140Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, James C. Foster 2026-08-25Form 42026-08-270001100682-26-000140Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Glenn Coleman 2026-09-30Form 42026-10-020001100682-26-000144Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Shannon M. Parisotto 2026-10-05Form 42026-10-070001952784-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Shannon M. Parisotto 2026-10-05Form 42026-10-070001952784-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Shannon M. Parisotto 2026-10-05Form 42026-10-070001952784-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
142Section 06, 2026 voteForm 8-K2026-05-050000950103-26-007060Item 5.07 · say-on-pay result. As reported: 93.84% (votes for as printed: 41,356,139). Filing ↗
143Section 06, 2025 voteForm 8-K2025-05-230001100682-25-000023Item 5.07 · say-on-pay result. As reported: 96.56% (votes for as printed: 40,218,870). Filing ↗
144Section 06, 2024 voteForm 8-K2024-05-100001100682-24-000020Item 5.07 · say-on-pay result. As reported: 95.02% (votes for as printed: 43,833,503). Filing ↗
145Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
146Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
147Section 09b board cost (computed)Computed——Cash 908,750 + equity 1,277,138 + all other 0 = 2,185,888, summed across the director compensation table rows.machine: formula: Σ = 2,185,888
148Thermo Fisher Scientific Inc., Section 10b CEO totalDEF 14A2026-04-070001193125-26-144585CEO total compensation as printed in Thermo Fisher Scientific Inc.'s own proxy. As printed: 79,923,350. Filing ↗machine: span 973487–973497
149Baxter International Inc., Section 10b CEO totalDEF 14A2026-03-230001628280-26-020330CEO total compensation as printed in Baxter International Inc.'s own proxy. As printed: 29,805,182. Filing ↗machine: r4 · c30 · span 1451066–1451076
150Gilead Sciences, Inc., Section 10b CEO totalDEF 14A2026-03-200001308179-26-000106CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592
151IQVIA Holdings Inc., Section 10b CEO totalDEF 14A2026-02-270001628280-26-012892CEO total compensation as printed in IQVIA Holdings Inc.'s own proxy. As printed: 28,128,245. Filing ↗machine: t232 · r4 · c10 · span 1613956–1613966
152Pfizer Inc., Section 10b CEO totalDEF 14A2026-03-120000078003-26-000033CEO total compensation as printed in Pfizer Inc.'s own proxy. As printed: 27,585,301. Filing ↗machine: t242 · r3 · c12 · span 1506825–1506835
153Amgen Inc., Section 10b CEO totalDEF 14A2026-04-070001193125-26-145588CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166
154Abbott Laboratories, Section 10b CEO totalDEF 14A2026-03-130001308179-26-000064CEO total compensation as printed in Abbott Laboratories's own proxy. As printed: 24,198,660. Filing ↗machine: span 1245488–1245498
155Biogen Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187303CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391
156Boston Scientific Corporation, Section 10b CEO totalDEF 14A2026-03-180000885725-26-000025CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. Filing ↗machine: r2 · c27 · span 1249807–1249817
157Bristol-Myers Squibb Company, Section 10b CEO totalDEF 14A2026-03-250000014272-26-000006CEO total compensation as printed in Bristol-Myers Squibb Company's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170
158Vertex Pharmaceuticals Incorporated, Section 10b CEO totalDEF 14A2026-04-020000875320-26-000153CEO total compensation as printed in Vertex Pharmaceuticals Incorporated's own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809
159Jazz Pharmaceuticals Public Company Limited, Section 10b CEO totalDEF 14A2026-06-080001232524-26-000029CEO total compensation as printed in Jazz Pharmaceuticals Public Company Limited's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379
160Becton, Dickinson and Company, Section 10b CEO totalDEF 14A2025-12-180001628280-25-057846CEO total compensation as printed in Becton, Dickinson and Company's own proxy. As printed: 17,129,140. Filing ↗machine: r2 · c27 · span 1173285–1173295
161Hologic Inc., Section 10b CEO totalDEF 14A2025-01-160001140361-25-001287CEO total compensation as printed in Hologic Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674
162Quest Diagnostics Incorporated, Section 10b CEO totalDEF 14A2026-04-060001140361-26-013356CEO total compensation as printed in Quest Diagnostics Incorporated's own proxy. As printed: 15,498,479. Filing ↗machine: r2 · c17 · span 699327–699337
163CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (subject), Section 10b CEO totalDEF 14A2026-03-310001104659-26-037367CEO total compensation as printed in CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s own proxy. As printed: 15,435,220. Filing ↗machine: r1 · c53 · span 1119658–1119668
164IDEXX Laboratories Inc., Section 10b CEO totalDEF 14A2026-03-270000874716-26-000064CEO total compensation as printed in IDEXX Laboratories Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018
165Waters Corporation, Section 10b CEO totalDEF 14A2026-04-090001193125-26-149657CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. Filing ↗machine: r5 · c18 · span 568522–568533
166Revvity, Section 10b CEO totalDEF 14A2026-03-160001193125-26-107266CEO total compensation as printed in Revvity's own proxy. As printed: 13,809,549. Filing ↗machine: r3 · c39 · span 751285–751295
167Agilent Technologies, Inc., Section 10b CEO totalDEF 14A2026-02-060001193125-26-040286CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992
168Fortrea Holdings, Inc., Section 10b CEO totalDEF 14A2026-04-270001193125-26-178733CEO total compensation as printed in Fortrea Holdings, Inc.'s own proxy. As printed: 11,584,483. Filing ↗machine: t114 · r4 · c39 · span 498934–498944
169STERIS plc, Section 10b CEO totalDEF 14A2026-06-110001193125-26-267599CEO total compensation as printed in STERIS plc's own proxy. As printed: 11,508,522. Filing ↗machine: t172 · r6 · c34 · span 820590–820600
170Medpace Holdings, Inc., Section 10b CEO totalDEF 14A2026-04-010001668397-26-000012CEO total compensation as printed in Medpace Holdings, Inc.'s own proxy. As printed: 11,443,766. Filing ↗machine: t43 · r3 · c9 · span 495770–495781
171Illumina, Inc., Section 10b CEO totalDEF 14A2026-04-090001193125-26-149669CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536
172Bio-Rad Laboratories, Inc., Section 10b CEO totalDEF 14A2026-03-250000012208-26-000020CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209
173Regeneron Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-240001308179-26-000340CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989
174Teleflex Incorporated, Section 10b CEO totalDEF 14A2026-04-130000096943-26-000039CEO total compensation as printed in Teleflex Incorporated's own proxy. As printed: 6,732,419. Filing ↗machine: span 558736–558745
175Catalent, Inc., Section 10b CEO totalDEF 14A2023-12-150001193125-23-295996CEO total compensation as printed in Catalent, Inc.'s own proxy. As printed: 6,583,672. Filing ↗machine: r3 · c31 · span 1055835–1055844
176Avantor, Inc., Section 10b CEO totalDEF 14A2026-03-270001628280-26-021572CEO total compensation as printed in Avantor, Inc.'s own proxy. As printed: 5,895,624. Filing ↗machine: r3 · c9 · span 2130032–2130041
177Myriad Genetics, Inc., Section 10b CEO totalDEF 14A2026-04-140000899923-26-000031CEO total compensation as printed in Myriad Genetics, Inc.'s own proxy. As printed: 5,686,740. Filing ↗machine: r2 · c24 · span 792986–792996
178Section 10a, Fortrea Holdings, Inc. reciprocityDEF 14A—0001193125-26-178733Fortrea Holdings, Inc. names CHARLES RIVER LABORATORIES INTERNATIONAL, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
179Section 10a, IDEXX Laboratories Inc. reciprocityDEF 14A—0000874716-26-000064IDEXX Laboratories Inc.'s most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
180Section 10a, Hologic Inc. reciprocityDEF 14A—0001140361-25-001287Hologic Inc.'s most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
181Section 10a, Catalent, Inc. reciprocityDEF 14A—0001193125-23-295996Catalent, Inc.'s most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
182Section 10a, Agilent Technologies, Inc. reciprocityDEF 14A—0001193125-26-040286Agilent Technologies, Inc. names CHARLES RIVER LABORATORIES INTERNATIONAL, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
183Section 10a, Gilead Sciences, Inc. reciprocityDEF 14A—0001308179-26-000106Gilead Sciences, Inc.'s most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
184Section 10a, Revvity reciprocityDEF 14A—0001193125-26-107266Revvity names CHARLES RIVER LABORATORIES INTERNATIONAL, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
185Section 10a, Amgen Inc. reciprocityDEF 14A—0001193125-26-145588Amgen Inc.'s most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
186Section 10a, Pfizer Inc. reciprocityDEF 14A—0000078003-26-000033Pfizer Inc.'s most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
187Section 10a, Avantor, Inc. reciprocityDEF 14A—0001628280-26-021572Avantor, Inc. names CHARLES RIVER LABORATORIES INTERNATIONAL, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
188Section 10a, Quest Diagnostics Incorporated reciprocityDEF 14A—0001140361-26-013356Quest Diagnostics Incorporated's most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
189Section 10a, Baxter International Inc. reciprocityDEF 14A—0001628280-26-020330Baxter International Inc.'s most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
190Section 10a, Regeneron Pharmaceuticals, Inc. reciprocityDEF 14A—0001308179-26-000340Regeneron Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
191Section 10a, Becton, Dickinson and Company reciprocityDEF 14A—0001628280-25-057846Becton, Dickinson and Company's most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
192Section 10a, STERIS plc reciprocityDEF 14A—0001193125-26-267599STERIS plc's most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
193Section 10a, IQVIA Holdings Inc. reciprocityDEF 14A—0001628280-26-012892IQVIA Holdings Inc.'s most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
194Section 10a, Teleflex Incorporated reciprocityDEF 14A—0000096943-26-000039Teleflex Incorporated's most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
195Section 10a, Jazz Pharmaceuticals Public Company Limited reciprocityDEF 14A—0001232524-26-000029Jazz Pharmaceuticals Public Company Limited's most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
196Section 10a, Boston Scientific Corporation reciprocityDEF 14A—0000885725-26-000025Boston Scientific Corporation's most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
197Section 10a, Vertex Pharmaceuticals Incorporated reciprocityDEF 14A—0000875320-26-000153Vertex Pharmaceuticals Incorporated's most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
198Section 10a, Bristol-Myers Squibb Company reciprocityDEF 14A—0000014272-26-000006Bristol-Myers Squibb Company's most recent proxy was read; its disclosed peer group does not include CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Filing ↗
199Section 10a, Medpace Holdings, Inc. reciprocityDEF 14A—0001668397-26-000012Medpace Holdings, Inc. names CHARLES RIVER LABORATORIES INTERNATIONAL, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
200Section 10a, Waters Corporation reciprocityDEF 14A—0001193125-26-149657Waters Corporation names CHARLES RIVER LABORATORIES INTERNATIONAL, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
CRL Peer Teardown Report